<DOC>
	<DOC>NCT01412047</DOC>
	<brief_summary>How does long term treatment with Soliris affect HAHA in PNH patients?</brief_summary>
	<brief_title>Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study</brief_title>
	<detailed_description>To determine the long term effect of Soliris (eculizumab) treatment on the presence of human anti-human antibodies (HAHA) in Paroxysmal Nocturnal Hemoglobinuria (PNH) patients.</detailed_description>
	<mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>PNH patients who previously participated in study E05001; Patients who have an eculizumab naive serum sample for comparison; Patients who currently used commerical Soliris; Patients who are willing and able to gie written informed consent. There are no exclusion criteria for this study.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Paroxysmal Nocturnal Hemoglobinuria</keyword>
	<keyword>PNH</keyword>
	<keyword>Human Anti-Human Antibody</keyword>
	<keyword>HAHA</keyword>
	<keyword>Soliris</keyword>
	<keyword>eculizumab</keyword>
</DOC>